Notice of Proposed Sale · 144
Opus Genetics, Inc.
IRDNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Opus Genetics, Inc.
- Issuer CIK
- 0001228627
- SEC file number
- 001-34079
- Phone
- (984) 884-6030
- Person for whose account securities are to be sold
- SCHACHLE JOSEPH K
- Relationships to issuer
- Officer
- Street
- 8 DAVIS DRIVE
- Street (continued)
- SUITE 220
- City
- DURHAM
- State / country code
- NC
- Postal code
- 27713
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 4,644 | 13,653.36 | 82,570,000 | 07/23/2026 | NASDAQ | Raymond James & Associates |
Broker / market maker — proposed row 1, entry 1
- Name
- Raymond James & Associates
- Street
- 880 Carillon Parkway
- City
- St. Petersburg
- State / country code
- FL
- Postal code
- 33716
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 07/22/2026 | RSU Grant Vest | Issuer | 15,625 | N | 07/23/2026 | Cash |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| JOSEPH SCHACHLE c/o OPUS GENETICS, INC | Common | 04/23/2026 | 4,697 | 24,519.00 |
Seller — prior-sale row 1, entry 1
- Name
- JOSEPH SCHACHLE c/o OPUS GENETICS, INC
- Street
- 8 DAVIS DRIVE
- City
- Durham
- State / country code
- NC
- Postal code
- 27713
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Remarks
THE TRADES ARE NOT DISCRETIONARY AS THEY ARE REQUIRED TO COVER TAX OBLIGATIONS
Notice signature
- Notice date
- 07/23/2026
- Signed
- Rashida Mitchell, as duly authorized representative of Raymond James & Associates, Inc., as attorney-in-fact for Joseph Schachle
Company context
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RDH12, MERTK, RHO, CNGB1 and NMNAT1. The Company is based in Research Triangle Park, NC. For more information, visit www.opusgtx.com.